Eli Lilly and Co (LLY) Actualités

Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease

Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy...

Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab

Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers

Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lilly confirms date and conference call for third-quarter 2024 financial results announcement

Lilly confirms date and conference call for third-quarter 2024 financial results announcement PR...

Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies

Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during...

Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease

Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's...

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

October 2, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Alzheimer’s disease (“AD”) has become a...

Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials

Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production...

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in...